ArticleMolecular therapy. Methods & clinical development2020
Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy.
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules.Discover oncology · 2026Review
- mRNA-based therapies: current progress and future prospects for treating kidney disease.Clinical and experimental nephrology · 2026Review
- Dendritic Cells: Orchestrators of Immune Responsiveness and Tolerance.Immunological reviews · 2025Review
- mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2025Review
- Applications of microfluidics in mRNA vaccine development: A review.Biomicrofluidics · 2024Review
- Lipid nanoparticle-mediated RNA delivery for immune cell modulation.European journal of immunology · 2024Review
- Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.Journal of nanobiotechnology · 2024Review
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment.Pharmaceutics · 2024Review
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.Medical sciences (Basel, Switzerland) · 2024Review
- Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications.3 Biotech · 2024Review
- Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.Frontiers in immunology · 2024Review
- Epitope-based precision immunotherapy of Type 1 diabetes.Human vaccines & immunotherapeutics · 2023Article
- The use of RNA-based treatments in the field of cancer immunotherapy.Molecular cancer · 2023Review
- A Comprehensive Review of mRNA Vaccines.International journal of molecular sciences · 2023Review
- Frontiers in hepatic drug delivery-grand challenges.Frontiers in drug delivery · 2023Article
- Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects.Journal of nanobiotechnology · 2022Review
- Transfection by Electroporation of Cancer and Primary Cells Using Nanosecond and Microsecond Electric Fields.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The efficacy of antigen-specific immunotherapy relies heavily on efficient antigen delivery to antigen-presenting cells and engagement of as many disease-relevant T cells as possible in various lymphoid tissues, which are challenging to achieve. Here, we compared two approaches to deliver mRNA encoding multiple epitopes targeting both CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.